I-MAB
IMAB
Company Profile
Business description
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Contact
2440 Research Boulevard
Suite 400
RockvilleMD20850
USAT: +1 240 745-6330
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
220
I-MAB News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,450.90 | 64.30 | -0.76% |
CAC 40 | 7,226.98 | 199.90 | -2.69% |
DAX 40 | 19,033.64 | 414.96 | -2.13% |
Dow JONES (US) | 43,910.98 | 382.15 | -0.86% |
FTSE 100 | 8,025.77 | 99.42 | -1.22% |
HKSE | 19,705.97 | 140.91 | -0.71% |
NASDAQ | 19,281.40 | 17.36 | -0.09% |
Nikkei 225 | 38,716.37 | 659.72 | -1.68% |
NZX 50 Index | 12,674.49 | 74.87 | -0.59% |
S&P 500 | 5,983.99 | 17.36 | -0.29% |
S&P/ASX 200 | 8,193.40 | 62.20 | -0.75% |
SSE Composite Index | 3,428.77 | 6.80 | 0.20% |